‘Underdiagnosed and undertreated’: Recognizing World Sjögren’s Day
Click Here to Manage Email Alerts
Dry eye in Sjögren’s syndrome remains “underdiagnosed and undertreated,” and often not fully understood, according to Sjögren Europe, which is gearing up for World Sjögren’s Day on July 23 with a campaign aimed at raising awareness online.
Throughout much of July, Sjögren Europe, the European federation of Sjögren’s syndrome patient associations, has shared tips on Twitter for tackling some of the symptoms associated with Sjogren’s syndrome, like dry eye disease.
“Dry eye is still underdiagnosed and undertreated,” Sjögren Europe site states. “There are still people with Sjögren’s who remain undiagnosed. There are numerous reasons for this, but often because the threshold to refer to a specialist for dry eye may be higher than for other conditions.”
According to the group, there have been significant advances in dry eye treatment over the past few years, including newer lubricating drops to replace specific parts of the tear film, which address inflammation and have a more lasting impact. In addition, specialist contact lenses can keep the surface of the eye well hydrated while the lens is in place, the group counsels on its website.
“These lenses have a rigid shape which hold fluid within them creating an interface between the lens and the surface of the eye,” the Sjögren Europe site continues. “When fitted by a specialist, they can be very effective in certain severe cases.”
recognition of World Sjögren’s Day, Healio Rheumatology has compiled its top five stories featuring Sjögren’s Syndrome from the past year. These stories cover current and emerging treatments, outcome measures and the challenges in making a diagnosis.
'Oft-neglected' Sjögren's syndrome now second most common autoimmune disease
Myriad symptoms and three different sets of classification criteria make Sjögren's syndrome a challenging diagnosis, according to a presenter at the Congress of Clinical Rheumatology East. Read more.
'Promising treatments' for Sjögren’s syndrome may enter clinical use in 3 to 5 years
It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West. Read more.
Sjögren’s syndrome ‘not curable, but certainly treatable’ with available therapies
Although not currently curable, the symptoms of Sjögren’s syndrome, like dry eyes and dry mouth, can be effectively managed using a variety of therapies, said a speaker said at the Congress of Clinical Rheumatology East 2022 meeting. Read more.
Sjögren's drug pipeline prepares for 'next wave' after longtime lapse in therapies
Novel therapeutic approaches and a robust drug pipeline may provide hope for patients with Sjögren’s syndrome, according to a presenter at the 2021 Congress of Clinical Rheumatology-East. Read more.
STAR aims to be ‘gold standard’ for outcome measures in Sjögren’s syndrome
The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers. Read more.
References:
@SjogrenEurope. https://twitter.com/SjogrenEurope/status/1545432785137057794. July 8, 2022. Accessed July 19, 2022.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts